Savara Inc (NASDAQ:SVRA) Director David A. Ramsay Buys 39,906 Shares

Savara Inc (NASDAQ:SVRAGet Rating) Director David A. Ramsay purchased 39,906 shares of the stock in a transaction on Friday, June 17th. The shares were purchased at an average price of $1.33 per share, with a total value of $53,074.98. Following the acquisition, the director now owns 1,541,048 shares in the company, valued at approximately $2,049,593.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of SVRA stock opened at $1.49 on Thursday. The company has a market cap of $169.92 million, a price-to-earnings ratio of -5.73 and a beta of 1.06. Savara Inc has a 52 week low of $1.02 and a 52 week high of $1.82. The company has a quick ratio of 9.47, a current ratio of 9.47 and a debt-to-equity ratio of 0.10. The firm has a 50 day moving average of $1.29 and a 200-day moving average of $1.24.

Savara (NASDAQ:SVRAGet Rating) last posted its quarterly earnings results on Wednesday, March 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). Analysts anticipate that Savara Inc will post -0.27 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp grew its position in Savara by 12.4% in the 1st quarter. State Street Corp now owns 271,611 shares of the company’s stock valued at $356,000 after purchasing an additional 30,062 shares during the period. Two Sigma Advisers LP grew its position in Savara by 8.4% in the 3rd quarter. Two Sigma Advisers LP now owns 757,015 shares of the company’s stock valued at $1,045,000 after purchasing an additional 58,900 shares during the period. Two Sigma Investments LP grew its position in Savara by 15.9% in the 3rd quarter. Two Sigma Investments LP now owns 501,757 shares of the company’s stock valued at $692,000 after purchasing an additional 68,834 shares during the period. Geode Capital Management LLC grew its position in Savara by 6.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,198,160 shares of the company’s stock valued at $1,653,000 after purchasing an additional 70,341 shares during the period. Finally, Marquette Asset Management LLC bought a new position in Savara during the 4th quarter valued at $116,000. 71.64% of the stock is owned by institutional investors and hedge funds.

Savara Company Profile (Get Rating)

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Recommended Stories

Insider Buying and Selling by Quarter for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.